Why Timing Matters in Cancer Therapy

Understanding the success rate of Targeted Metabolic Therapy over time First, we have to make clear that there is always hope. We’ve seen remarkable recoveries even in stage 4 and hospice cases — when the right protocol is applied with full commitment. Metabolic therapy works at every stage, but the chances are highest when we […]

TARGETED METABOLIC CANCER THERAPY CASE REPORT: Borderline High-Risk Prostate Cancer Shows Rapid PSA Reduction (–46%), Near-Complete Inflammation Resolution (–99%), and Hormonal Rebalancing Within 1 Month

Patient profile Age: 65 yearsSex: Male Clinical History Diagnosis (2025) BLOOD MARKER EVOLUTION (29 Dec 2025 → 30 Jan 2026) Marker Before After Interpretation PSA (ng/mL) 5.7 3.1 –46% CRP (mg/L) 62 0.8 –99% CEA 1.43 0.96 Reduced RBC 4.88 4.98 Stable WBC 8.91 7.9 Normalized Hemoglobin (g/dL) 13.9 13.9 Stable Lymphocytes (abs) 4.12 4.32 Strong immune […]

TARGETED METABOLIC CANCER THERAPY CASE REPORT: Stage IV Pancreatic Cancer With Liver Metastases Achieves No Evidence of Disease (NED) After 14 Months of Combined Immunotherapy and Metabolic Intervention

BACKGROUND Patient: 59-year-old maleCancer Type: Pancreatic adenocarcinomaStage at Diagnosis: Stage IVMetastatic Site: LiverTime Since Diagnosis: ~14 months Pancreatic cancer is among the most aggressive solid tumors, with poor outcomes once metastatic. This case is notable for early metabolic intervention combined with immunotherapy, resulting in sustained disease control. TUMOR & DISEASE CHARACTERISTICS CURRENT CANCER STATUS Overall […]

TARGETED METABOLIC CANCER THERAPY CASE REPORT: Metastatic Poorly Differentiated NSCLC Shows ~80% Reduction in Tumor Activity Markers and Complete Inflammation Reversal Over 4 Months

BACKGROUND Diagnosis: Metastatic poorly differentiated non-small cell lung adenocarcinoma (NSCLC)Primary tumor: Right lower lobeStage: Advanced metastatic disease Documented Metastatic Spread (PET-CT, 23 April 2025) This represents a high-burden, poorly differentiated metastatic lung cancer, typically associated with rapid progression, severe inflammation, high LDH, anemia, bone involvement, and hypercoagulability. The patient has been following Targeted Metabolic Therapy […]

TARGETED METABOLIC CANCER THERAPY CASE REPORT (Ivermectin, Fenbendazole, CDS, Ketogenic diet & more…), 34% reduction in PSA in 4 weeks.

64-Year-Old Male With Metastatic Prostate Cancer, Lung Masses & Liver Lesions — Baseline Status and 4-Week Metabolic Response BACKGROUND PET/CT imaging confirmed aggressive, multi-system metastatic disease: Despite no local recurrence in the prostate bed, the cancer is clearly progressing systemically. Baseline PSA: 43.8 ng/mL BASELINE METABOLIC STATUS (Before protocol) Marker Before Interpretation Fasting Glucose 107.4 […]

Treatment Protection Protocol

Enter your details below, and I’ll send the complete “Treatment Protection ” protocol straight to your inbox. Get all the essential facts and benefits at your fingertips!